Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
Authors
Kelderman, SHeemskerk, B
van Tinteren, H
van den Brom, R
Hospers, G
van den Eertwegh, A
Kapiteijn, E
de Groot, J
Soetekouw, P
Jansen, R
Fiets, E
Furness, A
Renn, A
Krzystanek, M
Szallasi, Z
Lorigan, Paul C
Gore, M
Schumacher, T
Haanen, J
Larkin, J
Blank, C
Affiliation
Netherlands Cancer Institute NKI-AVL, Plesmanlaan 121, 1066 CX, Amsterdam, The NetherlandsIssue Date
2014-05
Metadata
Show full item recordAbstract
Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody, has improved overall survival (OS) in metastatic melanoma in phase III trials. However, about 80 % of patients fail to respond, and no predictive markers for benefit from therapy have been identified. We analysed a 'real world' population of patients treated with ipilimumab to identify markers for treatment benefit.Citation
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. 2014, 63 (5):449-58 Cancer Immunol ImmunotherJournal
Cancer Immunology, ImmunotherapyDOI
10.1007/s00262-014-1528-9PubMed ID
24609989Type
ArticleLanguage
enISSN
1432-0851ae974a485f413a2113503eed53cd6c53
10.1007/s00262-014-1528-9